Solaxa announces plan for phase 3 clinical trial for SCA27B
In March, the pharmaceutical company Solaxa has announced plans to conduct a phase 3 clinical trial of their drug SLX-100 (repurposed 4-aminopyridine) for Spinocerebellar ataxia 27B (SCA27B). The trial will […]
Solaxa announces plan for phase 3 clinical trial for SCA27B Read More »